DBV technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®.
Location: France, Ile-de-France, Montrouge
Employees: 51-200
Total raised: $307.04M
Founded date: 2002
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.07.2015 | - | $281.5M | - |
| 05.01.2011 | Series C | $25.54M | - |
Mentions in press and media 22
| Date | Title | Description | Source |
| 08.03.2024 | DBV Technologies announces filing of 2023 Annual Report on F... | - | globenewsw... |
| 04.03.2024 | Allergy Immunotherapy Market Demand Analysis and Opportunity... | Allergy Immunotherapy Allergy Immunotherapy Market Review: All Eyes on 2024 Outlook Stay up to date ... | einpresswi... |
| 04.03.2024 | DBV Technologies to Report Full Year 2023 Financial Results ... | Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Bus... | einpresswi... |
| 04.03.2024 | DBV Technologies présentera ses résultats financiers pour l’... | Montrouge, France, le 4 mars (22h30 CET) 2024 DBV Technologies présentera ses résultats financiers p... | einpresswi... |
| 09.06.2022 | DBV Technologies Announces Private Placement Financing of $1... | Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Milli... | globenewsw... |
| 04.05.2022 | DBV Technologies Completes ADSs Sale of an amount of $15.3 m... | Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $15.3 million on... | globenewsw... |
| 26.10.2021 | DBV Technologies Reports Third Quarter 2021 Financial Result... | DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments DBV... | marketscre... |
| 28.04.2021 | DBV TECHNOLOGIES S.A. DBV Technologies S A : AGM 2021 – US ... | DBV Technologies S.A. Proxy Statement for the 2021 Annual Combined General Meeting of Shareholders D... | marketscre... |
| 18.03.2020 | FDA cancels AdCom meeting for DBV’s peanut allergy patch, ci... | Shares of DBV were down 56% on the Euronext Paris when that market closed Tuesday. They were also do... | medcitynew... |
| 17.03.2020 | In another win for rival Aimmune, FDA presses pause on ... | Another regulatory setback has strayed DBV Therapeutics’s peanut allergy patch off the p... | endpts.com... |
Show more